CEPHEUS Highlights Efficacious, Safe Regimen for Transplant‑Ineligible/Deferred Multiple Myeloma
Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.
The phase 3 CEPHEUS trial demonstrates that adding subcutaneous daratumumab to the standard VRd backbone yields superior depth of response, minimal residual disease–negative rates, and improved progression‑free survival in transplant‑ineligible or transplant‑deferred newly diagnosed multiple myeloma patients, providing a well‑tolerated, effective first‑line option for a patient population traditionally lacking robust therapeutic alternatives.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy